RecruitingNot ApplicableNCT07213154

Optical Imaging Scans for the Diagnosis of Skin Cancer in Patients With Lesions

Assessment of Novel Label-free Optical Imaging Technology for the Evaluation of Skin Lesions

Sponsor

Emory University

Enrollment

10 participants

Start Date

Oct 15, 2025

Study Type

INTERVENTIONAL

Conditions

Skin Neoplasm Malignant Skin Neoplasm Skin Disorder

Summary

This clinical trial studies how well an optical imaging scan called quantitative oblique back-illumination microscopy (qOBM) helps in diagnosing skin cancer in patients with skin lesions. qOBM is a non-invasive procedure that uses red light for illumination, and may work better than no imaging procedures in aiding doctors in diagnosing skin lesions.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called Quantitative Oblique Back-Illumination Microscopy and Radiation Therapy for people with malignant skin neoplasm, skin disorder, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREQuantitative Oblique Back-Illumination Microscopy

Undergo qOBM

RADIATIONRadiation Therapy

Undergo SOC RT

Locations(2)

Emory University Hospital Midtown

Atlanta, Georgia, United States

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07213154

Related Trials

Minibeam Radiation Therapy With Tungsten Slit Collimator for the Treatment of Recurrent or Metastatic Skin or Soft Tissue Tumors

NCT070620031 location

Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App

NCT066756431 location

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

NCT0578671627 locations